Immunoglobulins in neurological practice: a review of the literature
https://doi.org/10.17650/2222-8721-2019-9-1-32-51
Abstract
Today intravenous immunoglobulins are used increasingly in the management of patients with neurological conditions. The efficacy and safety of intravenous immunoglobulins treatment in chronic inflammatory demyelinating polyradiculoneuropathy, Guillain–Barre syndrome and multifocal motor neuropathy have been established in randomized controlled trials and declared in systematic reviews. There are discussions about the dose, timing, duration and necessity of repeated infusions in these disorders. The intravenous immunoglobulins treatment is an option in myasthenia gravis crisis and exacerbations the disease, stiff-person syndrome, a second-line therapy in dermatomyositis and some patients with polymyositis. The use of intravenous immunoglobulins in patients with multiple sclerosis, inclusion body myositis, resistant epilepsy is not finally proved. The review discussed the data of immunoglobulins efficacy in neurological disorders based on informative studies with an emphasis on the main criteria for choosing a drug for effective high-dose intravenous immunotherapy.
About the Authors
S. S. Nikitin
Medical Center “Practical Neurology”;
Association of Neuromuscular Disorders Specialists
Russian Federation
Russian Federation
Build. 2, 17 Krzhizhanovskogo St., Moscow 117258,
Build 15, 24 Kashirskoe Shosse, Moscow 117478
L. M. Boriskina
Association of Neuromuscular Disorders Specialists;
“Normodent Center” «Clinic Central»
Russian Federation
Russian Federation
Build 15, 24 Kashirskoe Shosse, Moscow 117478,
Build 13, 13 Myasnitskaya St., Moscow 101000
References
1. Cohn E.J., Strong L.E., Hughes W.L. et al. Preparation and properties of serum and plasma proteins; a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946;68:459–75. PMID: 21015743. DOI: 10.1021/ja01207a034.
2. Casadeval A., Dadachova E., Pirofski L.A. Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2004;2(9):695–703. PMID: 15372080. DOI: 10.1038/nrmicro974.
3. Martin P.R., Scheidegger J.J., Wenger P. et al. Behavior of intramuscular, intravenous and oral gamma globulin. Blut 1959;5(2):104–14. PMID: 13671094.
4. Schultze H.E., Schwick G., Bikhard J. On the antibody nature of properdin. Z Immun Exp Ther 1962;123:307–25. PMID: 13987245.
5. Barandum S., Kistler P., Jeunet F., Isliken H. Intravenous administration of human gamma-globulin. Vox Sang 1962;7:157–74. PMID: 13864762. DOI: 10.1159/000464763.
6. Intravenous immunoglobulin: prevention and treatment of disease. NIH Consens State Sci Statements 2004;21(1):1–23. PMID: 17308551.
7. Imbach P., Barandun S., d’Apuzzo V. et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1(8232):1228–31. PMID: 6112565. DOI: 10.1016/s0140-6736(81)90810-2.).
8. Wahn V., Orange J.S. Clinical use of immunoglobulins. 2nd edition. Bremen: Uni-Med, 2013. P. 251.
9. McLeod J.G., Pollard J.D., Macaskill P. et al. Prevalence of chronic inflammatory demyelinating polyneuropathy in New South Wales, Australia. Ann Neurol 1999;46:910–3. PMID: 10589544. DOI: 10.1002/1531-8249(199912)46:6<910::aid-ana14>3.0.co;2-2.
10. Baranov A.A., NamazovaBaranova L.S., Kurenkov A.L. et al. Chronic inflammatory demyelinating polyneuropathy. Clinical guidelines. Electronic edition, 2016. P. 6. (In Russ.).
11. Patwa H.S., Chaudhry V., Katzberg H. et al. Evidence-based guideline: intravenous immunoglobulin in the treatment of neuromuscular disorder: report of the therapeutics and technology assessment subcommittee of the American academy of neurology. Neurology 2012;78(13):1009–15. PMID: 22454268. DOI: 10.1212/WNL.0b013e31824de293.
12. Hughes R.A., Donofrio P., Bril V. et al. Intravenous immuneglobulin (10 % caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomized placebocontrolled trial. Lancet Neurol 2008;7:136–44. PMID: 18178525. DOI: 10.1016/S1474-4422(07)70329-0.
13. Mendell J.R., Barohn R.J., Freimer M.L. et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445–9. PMID: 11222785. DOI: 10.1212/wnl.57.5.938.
14. Hahn A.F., Bolton C.F., Zochodne D., Feasby T.E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a doubleblind, placebo-controlled, cross-over study. Brain 1996;119:1067–77. PMID: 8813271. DOI: 10.1093/brain/119.4.1067.
15. Vermeulen M., van Doorn P.A., Brand A. et al. Intravenous immunoglobulintreatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebocontrolled study. J Neurol Neurosurg Psychiatry 1993;56:36–9. PMID: 8429321. DOI: 10.1136/jnnp.56.1.36.
16. Hughes R., Bensa S., Willison H. et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:195–201. PMID: 11506402. DOI: 10.1002/ana.1088.
17. Frenzel W., Wietek S., Svae T.E. et al. Tolerability and safety of octagamR (IVIG): a postauthorization safety analysis of four noninterventional phase IV trials. Int J Clin Pharmacol Ther 2016;54(11):847–55. PMID: 27719744. DOI: 10.1080/10245332.2017.1385892.
18. Wietek S. Octagam® for chronic inflammatory demyelinating polyneuropathy: results from three observational studies Neurodegener Dis Manag 2018;8(4):227–31. PMID: 29517417. DOI: 10.2217/nmt-2018-0006.
19. Kirgizov K.I., Skorobogatova E.V. Intravenous immunoglobulins: the use of modern physiological solutions can improve the results of therapy. Rossiyskiy Zhurnal Detskoy Gematologii I Onkologii = Russian Journal of Pediatric Hematology and Oncology 2015;2(2):77–83. (In Russ.). DOI:10.17650/2311-1267-2015-2-2-77-83.
20. Nevo Y. Childhood chronic inflammatory demyelinating polyneuropathy. Eur J Paediatr Neurol 1998;2(4):169–77. PMID: 10726588. DOI: 10.1016/s1090-3798(98)80016-0.
21. Eftimov F., Winer J.B., Vermeulen M. et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2009;(1):CD001797. PMID: 19160200. DOI: 10.1002/14651858.CD001797.pub2.
22. Rabie M., Nevo Y. Childhood acute and chronic immune-mediated polyradiculoneuropathies. Eur J Paediatr Neurol 2009;13(3):209–18. PMID: 18585069. DOI: 10.1016/j.ejpn.2008.04.009.
23. Lucke M.I., Adrichem M.E., Wieske L. et al. Intravenous immunoglobulins in patients with clinically suspected chronic immune-mediated neuropathy. J Neurol Sci 2019;397:141–5. PMID: 30623818. DOI: 10.1016/j.jns.2018.12.036.
24. Suponeva N.A., Piradov M.A. Intravenous immunotherapy in neurology. Moscow: Goryachaya liniya–Telecom, 2013. P. 312. (In Russ.).
25. Raphael J.C., Chastang C., Jais J.P. et al. French Cooperative Group on Plasma Exchange in Guillain–Barre syndrome. Efficiency of plasma exchange in Guillain–Barre syndrome: role of replacement fluids. Ann Neurol 1987;22(6):753–61. PMID: 2893583. DOI: 10.1002/ana.410220612.
26. GBS study group. Plasmapheresis and acute Guillain–Barre syndrome. The Guillain–Barre Syndrome Study Group. Neurology 1985;35:1096–104. PMID: 4022342. DOI:10.1212/WNL.35.8.1096
27. Raphael J.C., Chevret S., Harboun M. et al. Intravenous immune globulins in patients with Guillain–Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry 2001;71(2):235–8. PMID: 11459901. DOI: 10.1136/jnnp.71.2.235.
28. Koningsveld R., Steyerberg E.W., Hughes R.A. et al. A clinical prognostic scoring system for Guillain–Barre syndrome. Lancet Neurol 2007;6(7):589–94. PMID: 17537676. DOI: 10.1016/S1474-4422(07)70130-8.
29. Meche F.G., Schmitz P.I. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain–Barre syndrome. Dutch Guillain–Barre Study Group. N Engl J Med 1992;326(17):1123–9. PMID: 1552913. DOI: 10.1056/NEJM199204233261705.
30. Kleyweg R.P., van der Meche F.G. Treatment related fluctuations in Guillain–Barre syndrome after high-dose immunoglobulins or plasma-exchange. Neurol Neurosurg Psychiatry 1991;54(11):957–60. PMID: 1800666. DOI: 10.1136/jnnp.54.11.957.
31. Visser L.H., Schmitz P.I., Meulstee J. et al. Prognostic factors of Guillain–Barre syndrome after intravenous immunoglobulin or plasma exchange. Dutch Guillain–Barre Study Group. Neurology 1999;53(3):59–604. PMID: 10449126. DOI: 10.1212/wnl.53.3.598.
32. Bril V., Ilse W.K., Pearce R. et al. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain–Barre syndrome. Neurology 1996;46(1):100–3. PMID: 8559353. DOI: 10.1016/s0887-7963(96)80021-6.
33. PE/Sandoglobulin Guillain–Barre Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain–Barre syndrome. Lancet 1997;349(9047):225–30. PMID: 9014908. DOI: 10.1016/s0140-6736(96)09095-2.
34. Ortiz-Salas P., Velez-Van-Meerbeke A., Galvis-Gomez C.A., Rodriguez Q.J. Human immunoglobulin versus plasmapheresis in Guillain–Barre syndrome and myasthenia gravis: a meta-analysis. J Clin Neuromuscul Dis 2016;18(1):1–11. DOI: 10.1097/CND.0000000000000119.
35. Haupt W.F., Birkmann C., van der Ven C., Pawlik G. Apheresis and selective adsorption plus immunoglobulin treatment in Guillain–Barre syndrome. Ther Apher 2000;4(3):198–200. PMID: 10910019. DOI: 10.1046/j.1526-0968.2000.00182.x.
36. Koningsveld R., Schmitz P.I., Meche F.G. et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain–Barre syndrome: randomised trial. Lancet 2004;363(9404):192–6. PMID: 14738791. DOI: 10.1016/s0140-6736(03)15324-x.
37. Kuitwaard K., de Gelder J., Tio-Gillen A.P. et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain–Barre syndrome. Ann Neurol 2009;66(5):597–603. PMID: 19938102. DOI: 10.1002/ana.21737.
38. Godoy D.A., Rabinstein A. Is a second cycle of immunoglobulin justified in axonal forms of Guillain–Barre syndrome? Arq Neuropsiquiatr 2015;73(10):848–51. PMID: 26465402. DOI: 10.1590/0004-282X20150136.
39. Walgaard C., Jacobs B.C., Lingsma H.F. et al. Second IVIg course in Guillain– Barre syndrome patients with poor prognosis (SID-GBS trial): Protocol for a double-blind randomized, placebocontrolled clinical trial. J Peripher Nerv Syst 2018;23(4):210–5. PMID: 30151941. DOI: 10.1111/jns.122860.
40. Hughes R.A., Swan A.V., van Doorn P.A. Intravenous immunoglobulin for Guillain–Barre syndrome. Cochrane Database Syst Rev 2010;(6):CD002063. PMID: 20556755. DOI: 10.1002/14651858.CD002063.pub4.
41. Kuwabara S., Mori M., Ogawara K. et al. Intravenous immunoglobulin therapy for Guillain–Barre syndrome with IgG anti-GM1 antibody. Muscle Nerve 2001;24(1):54–8. PMID: 11150966. DOI: 10.1002/1097-4598(200101)24:1<54::aid-mus6>3.0.co;2-9.
42. Romano J.G., Rotta F.T., Potter P. et al. Relapses in the Guillain–Barre syndrome after treatment with intravenous immune globulin or plasma exchange. Muscle Nerve 1998;21(10):1327–30. PMID: 9736064. DOI: 10.1002/(sici)1097-4598(199810)21:10<1327::aidmus14>3.3.co;2-9.
43. Odaka M., Tatsumoto M., Hoshiyama E. et al. Side effects of combined therapy of methylprednisolone and intravenous immunoglobulin in Guillain–Barre syndrome. Eur Neurol 2005;53(4):194–6. PMID: 15970631. DOI: 10.1159/000086477.
44. Ceccarelli M., Pifferi M., Simoni F. et al. Initial experiences in the use of intravenous immunoglobulins in Guillain–Barre–Strohl syndrome. Pediatr Med Chir 1987;9(6):719–21. PMID: 3444744.
45. Rapin F., Astruc J., Echenne B., Rodière M. Pediatric use of intravenous immunoglobulins in immunomodulation. Apropos of 34 cases. Current data. Ann Pediatr (Paris) 1988;35(7):481–8. PMID: 3178111.
46. Nicolaides P., Appleton R.E. Immunoglobulin therapy in Guillain– Barre syndrome in children. Dev Med Child Neurol 1995;37(12):1110–4. PMID: 8566469. DOI: 10.1111/j.1469-8749.1995.tb11972.x.
47. Vallee L., Dulac O., Nuyts J.P. et al. Intravenous immune globulin is also an efficient therapy of acute Guillain– Barre syndrome in affected children. Neuropediatrics 1993;24(4):235–6. PMID: 8232785. DOI: 10.1055/s-2008-1071548.
48. Yata J., Nihei K., Ohya T. et al. High-dose immunoglobulin therapy for Guillain– Barre syndrome in Japanese children. Pediatr Int 2003;45(5):543–9. PMID: 14521529. DOI: 10.1046/j.1442-200x.2003.01768.x.
49. Korinthenberg R., Schessl J., Kirschner J., Mönting J.S. Intravenously administered immunoglobulin in the treatment of childhood Guillain–Barre syndrome: a randomized trial. Pediatrics 2005;116(1):8–14. PMID: 15995024. DOI: 10.1542/peds.2004-1324.
50. Gürses N., Uysal S., Cetinkaya F. et al. Intravenous immunoglobulin treatment in children with Guillain–Barre syndrome. Scand J Infect Dis 1995;27(3):241–3. PMID: 8539548. DOI: 10.3109/00365549509019016.
51. Vajsar J., Sloane A., Wood E., Murphy E.G. Plasmapheresis vs intravenous immunoglobulin treatment in childhood Guillain–Barre syndrome. Arch Pediatr Adolesc Med 1994;148(11):1210–2. PMID: 7921126. DOI: 10.1001/archpedi.1994.02170110096019.
52. Graf W.D., Katz J.S., Eder D.N. et al. Outcome in severe pediatric Guillain– Barre syndrome after immunotherapy or supportive care. Neurology 1999;52(7):1494–7. PMID: 10227643. DOI: 10.1212/wnl.52.7.1494.
53. Korinthenberg R., Mönting J.S. Natural history and treatment effects in Guillain– Barre syndrome: a multicentre study. Arch Dis Child 1996;74(4):281–7. PMID: 8669925. DOI: 10.1136/adc.74.4.281.
54. Reisin R.C., Pociecha J., Rodriguez E. et al. Severe Guillain–Barre syndrome in childhood treated with human immune globulin. Pediatr Neurol 1996;14(4):308–12. PMID: 8805174. DOI: 10.1016/0887-8994(96)00050-1.
55. Kanra G., Ozon A., Vajsar J. et al. Intravenous immunoglobulin treatment in children with Guillain–Barre syndrome. Eur J Paediatr Neurol 1997;1(1):7–12. PMID: 10728186. DOI: 10.1016/s1090-3798(97)80004-9.
56. McGhee B., Jarjour I.T. Single-dose intravenous immune globulin for treatment of Guillain–Barre syndrome. Am J Hosp Pharm 1994;51(1):97–9. PMID: 8135270. DOI: 10.1093/ajhp/51.1.97.
57. Shahar E., Shorer Z., Roifman C.M. et al. Immune globulins are effective in severe pediatric Guillain–Barre syndrome. Pediatr Neurol 1997;16(1):32–6. PMID: 9044398. DOI: 10.1016/s0887-8994(96)00253-6.
58. Pestronk A. Multifocal motor neuropathy: diagnosis and treatment. Neurology 1998;51(5):S22–4. PMID: 9851726. DOI: 10.1212/wnl.51.6_suppl_5.s22.
59. Bouche P., Moulonguet A., YounesChennoufi A.B. et al. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry 1995;59(1):38–44. PMID: 7608707. DOI: 10.1136/jnnp.59.1.38.
60. Schuchardt V., Hotz M., Hund E. et al. Experiences with high dosage immunoglobulin G in neuromuscular diseases. Nervenarzt 1993;64(2):98–103. PMID: 8450901.
61. Leger J.M., Chassande B., Musset L. et al. Intravenous immunoglobulin therapy in multifocal motor neuropathy: a doubleblind, placebo-controlled study. Brain 2001;124:145–53. PMID: 11133794. DOI: 10.1093/brain/124.1.145.
62. Federico P. Zochodne D.W., Hahn A.F. et al. Multifocal motor neuropathy improved by IVIg: randomized, doubleblind, placebo-controlled study. Neurology 2000;55:1256–62. PMID: 11087764. DOI: 10.1212/wnl.55.9.1256.
63. Azulay J.P., Blin O., Pouget J. et al. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology 1994;44:429–32. PMID: 8145910. DOI: 10.1212/wnl.44.3_part_1.429.
64. Van den Berg L.H., Kerkhoff H., Oey P.L. et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo-controlled study. J Neurol Neurosurg Psychiatry 1995;59(3):248–52. PMID: 7673950. DOI: 10.1136/jnnp.59.3.248.
65. Koski C., Beydoun S., Schiff R. et al. Efficacy, safety, and tolerability of intravenous gammaglobulin (IGIV, 10%) in a Phase 3, randomized, placebocontrolled, cross-over trial for the treatment of multifocal motor neuropathy (MMN). Neurology 2012;78(1):PL02.002. DOI: 10.1212/WNL.78.1_MeetingAbstracts.PL02.002.
66. Jinka M., Chaudhry V. Treatment of multifocal motor neuropathy. Curr Treat Options Neurol 2014;16(2):269. PMID: 24395647. DOI: 10.1007/s11940-013-0269-y.
67. Toyka K.V., Hartung H.P. Chronic inflammatory polyneuritis and neuropathies. Curr Opin Neurol 1996;9(3):240–50. PMID: 8839619. DOI: 10.1097/00019052-199606000-00016.
68. Van den Berg L.H., Franssen H., Wokke J.H. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 1998;121(Pt 3): 421–8. PMID: 9549518. DOI: 10.1093/brain/121.3.421.
69. Van den Berg-Vos R.M., Franssen H., Wokke J.H., Van den Berg L.H. Multifocal motor neuropathy: long-term clinical and electrophysiological assessment of intravenous immunoglobulin maintenance treatment. Brain 2002;125(Pt8):1875–86. PMID: 12135977. DOI: 10.1093/brain/awf193.
70. Nikitin S.S., Naumova E.S., D.S. Druzhinin. The sonographic dynamics of peripheral nerves cross sectional area changes in multifocal motor neuropathy treated with intravenous immunoglobulin: case report. Nervnomyshechnye Bolezni = Neuromuscular Diseases 2016;6(4):46–51. (In Russ.) DOI: 10.17650/2222-8721-2016-6-4-46-51.
71. Vucic S., Black K.R., Chong P.S., Cros D. Multifocal motor neuropathy: decrease in conduction blocks and reinnervation with long-term IVIg. Neurology 2004;63(7):1264–9. PMID: 15477549. DOI: 10.1212/01.wnl.0000140497.85952.fa.
72. Baumann A., Hess C.W., Sturzenegger M. IVIg dose increase in multifocal motor neuropathy: a prospective six month follow-up. J Neurol 2009;256(4):608–14. PMID: 19367358. DOI: 10.1007/s00415-009-0130-0.
73. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of paraproteinemic demyelinating neuropathies. Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. J Peripher Nerv Syst 2006;11(1):9–19. PMID: 16519778. DOI: 10.1111/j.1085-9489.2006.00059.x.
74. Comi G., Roveri L., Swan A. et al. A randomized controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 2002;249:1370–7. PMID: 12382151. DOI: 10.1007/s00415-002-0808-z.
75. Dalakas M.C., Quarles R.H., Farrer R.G. et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996;40(5):792–5. PMID: 8957021. DOI: 10.1002/ana.410400516.
76. Mariette X., Chastang C., Clavelou P. et al. A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 1997;63(1):28–34. PMID: 9221964. DOI: 10.1136/jnnp.63.1.28.
77. Fateh-Moghadam A., Besinger U., Wick M. High-dose immunoglobulin therapy in autoimmune diseases. Immun Infekt 1984;12(2):129–33. PMID: 6085502.
78. Ippoliti G., Cosi V., Piccolo G. et al. High dose intravenous gammaglobulin for myasthenia gravis. Lancet 1984;6:809. PMID: 6148545. DOI: 10.1016/s0140-6736(84)90729-3.
79. Arsura E.L., Bick A., Brunner N.G. et al. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986;146(7):1365–8. PMID: 3718134. DOI: 10.1001/archinte.1986.00360190143020.
80. Balzereit F., Fateh-Moghadam A., Besinger K. et al. Myasthenia gravis. Humorale diagnostic und therapie einer autoimmukrankheit. MMW 1986;128:654–7.
81. Gajdos P., Outin H., Morel E. et al. High dose intravenous gammaglobulin for myasthenia gravis: an alternative to plasma exchange? Ann N Y Acad Sci 1987;505:842–4. DOI: 10.1111/j.1749-6632.1987.tb51387.x.
82. Cosi V., Lombardi M., Piccolo G., Erbetta A. Treatment of myasthenia gravis with highdose intravenous immunoglobulin. Acta Neurol Scand 1991;84(2):81–4. PMID: 1950455. DOI: 10.1111/j.1600-0404.1991.tb04912.x.
83. Hilkevich O., Drory V.E., Chapman J., Korczyn A.D. The use of intravenous immunoglobulin as maintenance therapy in myasthenia gravis. Clin Neuropharmacol 2001;24(3):173–6. PMID 11391130. DOI: 10.1097/00002826-200105000-00010.
84. Uchiyama M., Ichikawa Y., Takaya M. et al. High dose gamma globulin therapy of generalized myasthenia gravis. Ann NY Acad Sci 1987;505:868–70. DOI: 10.1111/j.1749-6632.1987.tb51396.x.
85. Huang C.S., Hsu H.S., Kao K.P. et al. Intravenous immunoglobulin in the preparation of thymectomy for myasthenia gravis. Acta Neurol Scand 2003;108(2):136–8. PMID: 12859292. DOI: 10.1034/j.1600-0404.2003.00131.x.
86. Ronager J., Ravnborg M., Hermansen I., Vorstrup S. Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis. Artif Organs 2001;25(12):967–73. PMID: 11843764. DOI: 10.1046/j.1525-1594.2001.06717.x.
87. Liu J.F., Wang W.X., Xue J. et al. Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis. Ther Apher Dial 2010;14(2):153–60. PMID: 20438536. DOI: 10.1111/j.1744-9987.2009.00751.x.
88. Zinman L., Ng E., Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology 2007;68(11):837–41. PMID: 17353471. DOI: 10.1212/01.wnl.0000256698.69121.45.
89. Sakano T., Hamasaki T., Kinoshita Y. et al. Treatment for refractory myasthenia gravis. Arch Dis Child 1989;64(8):1191–3. PMID: 2782938. DOI: 10.1136/adc.64.8.1191.
90. Herrmann D.N., Carney P.R., Wald J.J. Juvenile myasthenia gravis: treatment with immune globulin and thymectomy. Pediatr Neurol 1998;18(1):63–6. PMID: 9492094. DOI: 10.1016/s0887-8994(97)00136-7.
91. Selcen D., Dabrowski E.R., Michon A.M., Nigro M.A. High-dose intravenous immunoglobulin therapy in juvenile myasthenia gravis. Pediatr Neurol. 2000;22(1):40–3. PMID: 10669204. DOI: 10.1016/s0887-8994(99)00112-5.
92. Bassan H., Muhlbaur B., Tomer A., Spirer Z. High-dose intravenous immunoglobulin in transient neonatal myasthenia gravis. Pediatr Neurol. 1998;18(2):181–3. PMID: 9535308. DOI: 10.1016/s0887-8994(97)00174-4.
93. Tagher R.J., Baumann R., Desai N. Failure of intravenously administered immunoglobulin in the treatment of neonatal myasthenia gravis. J Pediatr 1999;134(2):233–5. PMID: 9931536. DOI: 10.1016/s0022-3476(99)70422-1.
94. Stricker R.B., Kwiatkowska B.J., Habis J.A. et al. Myasthenic Crisis. Response to Plasmapheresis Following Failure of Intravenous γ-Globulin. Arch Neurol 1993;50(8):837–40. PMID: 8352670. DOI:10.1001/archneur.1993.00540080046012.
95. Achiron A., Barak Y., Miron S., Sarova‐ Pinhas I. Immunoglobulin treatment in refractory myasthenia gravis. Muscle Nerve 2000;4(23);551–5. PMID: 10716766. DOI: 10.1002/(sici)1097-4598(200004)23:4<551::aidmus14>3.3.co;2-f.
96. Gajdos P., Tranchant C., Clair B. et al. Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin: a randomized doubleblind clinical trial. Arch Neurol 2005;62(11):1689–93. PMID: 16286541. DOI: 10.1001/archneur.62.11.1689.
97. Gajdos P., Chevret S., Clair B. et al. Plasma exchange and intravenous immunoglobulin in autoimmune myasthenia gravis. Ann N Y Acad Sci 1998;841:720–6. PMID: 9668320. DOI: 10.1111/j.1749-6632.1998.tb11008.x
98. Qureshi A.I., Choudhry M.A., Akbar M.S. et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52(3):629–32. PMID: 10025801. DOI: 10.1212/wnl.52.3.629.
99. Barth D., Nabavi N.M., Ng E. et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 2011;76(23):2017–23. PMID: 21562253. DOI: 10.1212/WNL.0b013e31821e5505.
100. Gajdos P., Chevret S., Toyka K. Intravenous immunoglobulin for myasthenia gravis. Cochrane Database Syst Rev 2008;(1):CD002277. PMID: 18254004. DOI: 10.1002/14651858.CD002277.pub3.
101. Beecher G., Anderson D., Siddiqi Z.A. Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial. Neurology 2017;89(11):1135–41. PMID: 28814461. DOI: 10.1212/WNL.0000000000004365.
102. Dalakas M.C. Immunotherapy in myasthenia gravis in the era of biologics. Nat Rev Neurol 2019;15(2):113–24. PMID: 30573759. DOI: 10.1038/s41582-018-0110-z.
103. Bain P.G., Motomura M., Newsom-Davis J. et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the Lambert–Eaton myasthenic syndrome. Neurology 1996;47(3):678–83. PMID: 8797464. DOI: 10.1212/wnl.47.3.678.
104. Muchnik S., Losavio A.S., Vidal A. et al. Long-term follow-up of Lambert–Eaton syndrome treated with intravenous immunoglobulin. Muscle Nerve 1997;20(6):674–8. PMID: 9149073. DOI: 10.1002/(sici)1097-4598(199706)20:6<674::aid-mus3>3.0.co;2-5.
105. Rich M.M., Teener J.W., Bird S.J. Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin. Muscle Nerve 1997;20(5):614–5. PMID: 9140371. DOI: 10.1002/(sici)1097-4598(199705)20:5<614::aidmus13>3.0.co;2-w.
106. Takano H., Tanaka M., Koike R. et al. Effect of intravenous immunoglobulin in Lambert–Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve 1994;17(9):1073–5. PMID: 8065398. DOI: 10.1002/mus.880170919.
107. Okada A., Koike H., Nakamura T. et al. Efficacy of intravenous immunoglobulin for treatment of Lambert–Eaton myasthenic syndrome without antipresynaptic P/Q-type voltage-gated calcium channel antibodies: a case report. Neuromuscul Disord 2015;25(1):70–2. PMID: 25444432. DOI: 10.1016/j.nmd.2014.08.006.
108. Dalakas M.C., Illa I., Dambrosia J.M. et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med 1993;329(27):1993–2000. PMID: 8247075. DOI: 10.1056/NEJM199312303292704.
109. Cherin P., Herson S., Wechsler B. et al. Efficacy of intravenous gammaglobulin therapy in chronic refractory polymyositis and dermatomyositis: an open study with 20 adult patients. Am J Med 1991;91(2):162–8. PMID: 1714235. DOI: 10.1016/0002-9343(91)90009-m.
110. Cherin P., Herson S. Indications for intravenous gammaglobulin therapy in inflammatory myopathies. J Neurol Neurosurg Psychiatry 1994;57:50–4. PMID: 7964854. DOI: 10.1136/jnnp.57.suppl.50.
111. Cherin P., Piette J.C., Wechsler B. et al. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients. J Rheumatol 1994;21(6):1092–7. PMID: 7932419.
112. Cherin P., Pelletier S., Teixeira A. et al. Results and long-term follow up of intravenous immunoglobulin infusions in chronic, refractory polymyositis: an open study with thirty-five adult patients. Arthritis Rheum 2002;46(2):467–74. PMID: 11840450. DOI: 10.1002/art.10053.
113. Foreman C., Russo P., Davies N. et al. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients. Intern Med J 2017;47(1):112–5. PMID: 28076913. DOI: 10.1111/imj.13308.
114. Vermaak E., Tansley S.L., McHugh N.J. The evidence for immunotherapy in dermatomyositis and polymyositis: a systematic review. Clin Rheumatol 2015;34(12):2089–95. PMID: 26299472. DOI: 10.1007/s10067-015-3059-y.
115. Soueidan S.A., Dalakas M.C. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology 1993;43(5):876–9. PMID: 8492940. DOI: 10.1212/wnl.43.5.876.
116. Dalakas M.C., Sonies B., Dambrosia J. et al. Treatment of inclusion-body myositis with IVIg: a double-blind, placebocontrolled study. Neurology 1997;48(3):712–6. PMID: 9065553. DOI: 10.1212/wnl.48.3.712.
117. Dalakas M.C., Koffman B., Fujii M. et al. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology 2001;56(3):323–7. PMID: 11171896. DOI: 10.1212/wnl.56.3.323.
118. Walter M.C., Lochmüller H., Toepfer M. et al. High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study. J Neurol 2000;247(1):22–8. PMID: 10701893. DOI: 10.1007/s004150050005.
119. Poehlau D., Federlein J., Postert T. et al. Intravenous immunoglobulin (IVIG) treatment for patients with primary or secondary progressive multiple sclerosis - outline of a double-blind randomized, placebo-controlled trial. Mult Scler 1997;2(3):149–52. PMID: 9291171. DOI: 10.1177/135245859700300217.
120. Tselis A., Perumal J., Caon C. et al. Treatment of corticosteroid refractory optic neuritis in multiple sclerosis patients with intravenous immunoglobulin. Eur J Neurol 2008;15(11):1163–7. PMID: 18727675. DOI: 10.1111/j.1468-1331.2008.02258.x.
121. Elovaara I., Kuusisto H., Wu X. et al. Intravenous immunoglobulins are a therapeutic option in the treatment of multiple sclerosis relapse. Clin Neuropharmacol 2011;34(2):84–9. PMID: 21301327. DOI: 10.1097/WNF.0b013e31820a17f3.
122. Sorensen P.S., Haas J., Sellebjerg F. et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004;63(11):2028–33. PMID: 15596745. DOI: 10.1212/01.wnl.0000145798.61383.39.
123. Visser L.H., Beekman R., Tijssen C.C. et al. A randomized, double-blind, placebo-controlled pilot study of i.v. immune globulins in combination with i.v. methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004;10(1):89–91. PMID: 14760960. DOI: 10.1191/1352458504ms978sr.
124. Pöhlau D., Przuntek H., Sailer M. et al. Intravenous immunoglobulin in primary and secondary chronic progressive multiple sclerosis: a randomized placebo controlled multicentre study. Mult Scler 2007;13(9):1107–17. PMID: 17623736. DOI: 10.1177/1352458507078400.
125. Noseworthy J.H., O’Brien P.C., Weinshenker B.G. et al. IV immunoglobulin does not reverse established weakness in MS. Neurology 2000;55(8):1135–43. PMID: 11071491. DOI: 10.1212/wnl.55.8.1135.
126. Noseworthy J.H., O’Brien P.C., Petterson T.M. et al. A randomized trial of intravenous immunoglobulin in inflammatory demyelinating optic neuritis. Neurology 2001;56:1514–22. PMID: 11402108. DOI: 10.1016/s0002-9394(01)01226-0.
127. Stangel M., Boegner F., Klatt C.H. et al. Placebo controlled pilot trial to study the remyelinating potential of intravenous immunoglobulins in multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68(1):89–92. PMID: 10601410. DOI: 10.1136/jnnp.68.1.89.
128. Pechadre J.C., Sauvezie B., Osier C., Gibert J. The treatment of epileptic encephalopathies with gamma globulin in children (author’s transl). Rev Electroencephalogr Neurophysiol Clin 1977;7(4):443–7. PMID: 77033.
129. Duse M., Tiberti S., Plebani A. et al. IgG2 deficiency and intractable epilepsy of childhood. Monogr Allergy 1986;20:128–34. PMID: 3773903.
130. Engelen B.G., Renier W.O., Weemaes C.M. et al. Immunoglobulin treatment in epilepsy, a review of the literature. Epilepsy Res 1994;19(3):181–90. PMID: 7698094. DOI: 10.1016/0920-1211(94)90061-2.
131. Villani F., Avanzini G. The use of immunoglobulins in the treatment of human epilepsy. Neurol Sci 2002;23(1):S33–7. PMID: 12032585. DOI: 10.1007/s100720200013.
132. Rijckevorsel-Harmant K., Delire M., Schmitz-Moorman W., Wieser H.G. Treatment of refractory epilepsy with intravenous immunoglobulins. Results of the first double-blind/dose finding clinical study. Int J Clin Lab Res 1994;24(3):162–6. PMID: 7819596. DOI: 10.1007/bf02592447.
133. Aarli J.A. Immunological aspects of epilepsy. Brain Dev 1993;15(1):41–9. PMID: 8338210. DOI: 10.1016/0387-7604(93)90005-s.
134. Barontini F., Maurri S., Amantini A. “Epilepsia partialis continua” due to multifocal encephalitis: favourable outcome after immunoglobulin treatment. Ital J Neurol Sci 1994;15(3):157–61. PMID: 8056563. DOI: 10.1007/bf02339208.
135. Sandstedt P., Kostulas V., Larsson L.E. Intravenous gammaglobulin for postencephalitic epilepsy. Lancet 1984;8412(324):1154–5. PMID: 6209514. DOI: 10.1016/S0140-6736(84)91585-X.
136. Fayad M.N., Choueiri R., Mikati M. Landau–Kleffner syndrome: consistent response to repeated intravenous gammaglobulin doses: a case report. Epilepsia 1997;38(4):489–94. PMID: 9118856. DOI: 10.1111/j.1528-1157.1997.tb01740.x.
137. Lagae L.G., Silberstein J., Gillis P.L., Casaer P.J. Successful use of intravenous immunoglobulins in Landau–Kleffner syndrome. Pediatr Neurol 1998;18(2):165–8. PMID: 9535304. DOI: 10.1016/s0887-8994(97)00157-4.
138. Mikati M.A., Saab R. Successful use of intravenous immunoglobulin as initial monotherapy in Landau–Kleffner syndrome. Epilepsia 2000;41(7):880–6. PMID: 10897161. DOI: 10.1111/j.1528-1157.2000.tb00257.x.
139. Mikati M.A., Saab R., Fayad M.N., Choueiri R.N. Efficacy of intravenous immunoglobulin in Landau–Kleffner syndrome. Pediatr Neurol 2002;26(4):298–300. PMID: 11992758. DOI: 10.1016/s0887-8994(01)00402-7.
140. Mikati M.A., Kurdi R., El-Khoury Z. et al. Intravenous immunoglobulin therapy in intractable childhood epilepsy: openlabel study and review of the literature. Epilepsy Behav 2010;17(1):90–4. PMID: 20004620. DOI: 10.1016/j.yebeh.2009.10.020.
141. Karlson E.W., Sudarsky L., Ruderman E. et al. Treatment of stiff-man syndrome with intravenous immune globulin. Arthritis Rheum 1994;37(6):915–8. PMID: 8003064, DOI: 10.1002/art.1780370621.
142. Barker R.A., Marsden C.D. Successful treatment of stiff man syndrome with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry 1997;62(4):426–7. PMID: 9120475. DOI: 10.1136/jnnp.62.4.426.
143. Dalakas M.C., Fujii M., Li M. et al. Highdose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001;345(26):1870–6. PMID: 11756577. DOI: 10.1056/NEJMoa01167.
144. Cherin P., Cabane J. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. BioDrugs 2010;24(4):211–23. PMID: 20623988. DOI: 10.2165/11537660-000000000-00000.
145. Debes A., Bauer M., Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf 2007;16(9):1038–47. PMID: 17636556. DOI: 10.1002/pds.1449.
146. Wiles C.M., Brown P., Chapel H. et al. Intravenous immunoglobulin in neurological disease: a specialist review. J Neurol Neurosurg Psychiatry 2002;72(4):440–8. PMID: 11909900.
147. Maródi L. Regulation of antiinflammatory activity of intravenous immunoglobulin via inhibitory Fcγ- receptors. Pediatr Res 2001;50:551. DOI: 10.1203/00006450-200111000-00001.
148. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345(10):747–55. PMID: 11547745. DOI: 10.1056/nejmra993360.
149. Shah S. Pharmacy considerations for the use of IGIV therapy. Am J Health Syst Pharm 2005;62(16):S5–11. PMID: 16100386. DOI: 10.2146/ajhp050282.
150. Lemm G. Composition and properties of IVIg preparations that affect tolerability and therapeutic efficacy. Neurology 2002;59(12):S28–32. PMID: 12499468. DOI: 10.1212/wnl.59.12_suppl_6.s28.
151. Cherin P., Cabane J. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use. BioDrugs. 2010;24(4):211–23. PMID: 20623988. DOI: 10.2165/11537660-000000000-00000.
152. Kondratenko I.V., Bologov A.A. Intravenous Immunoglobulins, From Creation To The Present. Pediatriya = Pediatrics 2018;97(6):135–43. (In Russ.) DOI: 10.24110/0031-403X-2018-97-6-124-132.
153. Dantal J. Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol 2013;38:275–84. PMID: 24051350. DOI: 10.1159/000354893.
154. Debes A., Bauer M., Kremer S. Tolerability and safety of the intravenous immunoglobulin Octagam: a 10-year prospective observational study. Pharmacoepidemiol Drug Saf 2007;16(9):1038–47. PMID: 17636556. DOI: 10.1002/pds.1449.
Review
For citations:
Nikitin S.S., Boriskina L.M. Immunoglobulins in neurological practice: a review of the literature. Neuromuscular Diseases. 2019;9(1):32-51. (In Russ.) https://doi.org/10.17650/2222-8721-2019-9-1-32-51
Views:
2019
Email this article 